Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback